The Signos Glucose Monitoring System is a mobile device application that receives data from an OTC integrated continuous ...

HealthDay News — For patients 50 years or older at high cardiovascular risk without diabetes or prior stroke, an intensive systolic blood pressure (SBP) target (<120 mm Hg) seems cost-effective ...

In October 2024, Imuldosa received approval from the Food and Drug Administration based on data from the phase 3 Opportuniti ...

Following discussions with the FDA, it was decided that the NDA resubmission would seek accelerated approval for elamirpretide on the basis of improvement in knee extensor muscle strength.

OTC access linked to 31.8 percentage point increase in individuals moving from no contraceptive method to an effective method.

Exposure to vaginal estradiol not linked to increased rate of recurrent ischemic stroke when adjusted for comorbidity, medications, income, education ...

Benefits include reduced polyp size and severity of nasal symptoms at 24 weeks. HealthDay News — In adults with severe chronic rhinosinusitis with nasal polyps treated with a daily intranasal ...

Health systems can use electronic health record data to target households rather than just individuals, authors say. HealthDay News — Diabetes risk is commonly clustered within households ...

Dawnzera, a prekallikrein-directed antisense oligonucleotide, is supplied as a 80mg/0.8mL solution in a single-dose autoinjector.

The approval was supported by data from 3 double-blind, placebo-controlled trials that included a total of 1474 patients who met the 2016 ACR criteria for diagnosis of fibromyalgia.

AA clinical program includes 2 replicate pivotal studies assessing the safety and efficacy of upadacitinib in adults and adolescent patients with severe alopecia areata.